

Navigating prostate cancer screening in Canada for marginalized men through PSA screening and guidelines adherence

A call to action for policymakers

Nilanga Aki Bandara¹, Ryan Vethanayagam², Sandra Kim³, Marie-Pier St-Laurent³, Peter C. Black³, Miles Mannas³

¹Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; ²AbCellera Biologics Inc., Vancouver, BC, Canada; ³Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

Cite as: Bandara NA, Vethanayagam R, Kim S, et al. Navigating prostate cancer screening in Canada for marginalized men through PSA screening and guidelines adherence: A call to action for policymakers. *Can Urol Assoc J* 2024;18(9):E291-4. <http://dx.doi.org/10.5489/cuaj.8711>

Published online May 21, 2024

An estimated 24 600 men were newly diagnosed with prostate cancer (PCa) in Canada in 2022.¹ PCa still accounts for 10% of all male cancer deaths in 2022¹ and, therefore, remains a substantial public health concern. Large, randomized trials investigating screening for PCa have shown improvements in cancer-specific survival,^{2,3} providing level I evidence supporting population-based PCa screening with a shared decision-making approach.⁴ The Canadian, European, and American Urological Association guidelines⁴⁻⁶ all suggest that men who have a life expectancy of >10 years over the age of 50 should be offered prostate-specific antigen (PSA) screening. It is necessary for clinicians to discuss the benefits and harms associated with screening,⁴ so that patients can make an informed decision.

The benefits of screening include detection of cancer in localized disease stages, which leads to improved outcomes. On the other hand, some of the risks associated with PSA screening include exposure to invasive procedures such as prostate biopsies and the related risk of complications, risk of overtreatment in clinically insignificant PCa, short- or long-term impacts on bladder, bowel, and sexual function from treatment of PCa, and negative impacts on mental health.

PCa is most often asymptomatic when localized⁷ and currently, in many Canadian provinces, such as British Columbia, PSA screening for asymptomatic men is an uninsured benefit.⁸ Therefore, in British Columbia,

most men are required to pay a fee of \$35 for each PSA test.⁸ The financial costs associated with each PSA measurement may represent a recurrent barrier for some men to engage in PSA screening, even if they otherwise accept the potential risks associated with PCa screening. Moreover, the financial implications associated with screening may be inequitably borne by marginalized populations who are already at a higher risk for PCa. These marginalized populations include people of African and Indigenous ancestry.^{9,10}

It is well-known that Black men are disproportionately impacted by PCa. They are more likely to have PCa at a younger age and have more aggressive disease with greater PCa-specific mortality.⁹ The current American and European guidelines suggest that men who are of African descent and over the age of 45 should be offered PSA testing.^{5,6}

None of the guidelines currently address screening of Indigenous men in Canada or the U.S. Limited studies suggest that Indigenous men are less likely to undergo PSA screening and are perhaps at an increased risk of developing more aggressive disease than non-Indigenous men.¹⁰ Some of these differences, as with the African-American population, are likely related to the social determinants of health and access to care.¹¹

There is abundant evidence in the U.S. that the disproportionate impact of PCa on Black men is compounded by Black men having less access to PCa screening.¹¹ James et al reported in a systematic review that financial costs were a barrier to participation in screening for Black men living in the U.S.¹¹

Access to healthcare resources for Black men in Canada remains understudied and we do not have any evidence on the engagement of Black men in PCa screening in Canada.¹² It is necessary to take a context-specific analysis approach to understand the socioeconomic challenges that Black men living in Canada face compared to Black men living in the U.S. Access to healthcare is vastly different in Canada compared to the U.S, which may facilitate easier access to PSA screening for Black men in Canada. In Canada,

KEY MESSAGES

- In 2022, prostate cancer diagnoses in Canada exceeded 20 000 cases, accounting for approximately 10% of male cancer-related deaths during the same period.
- Large, randomized trials support population-based prostate cancer screening, emphasizing a shared decision-making approach.
- According to various guidelines, men 50–69 years of age are recommended to undergo PSA screening.
- Financial barriers, including the expense of PSA tests, presents challenges to widespread screening, potentially impacting marginalized populations such as individuals of African and Indigenous ancestry.

healthcare is provided mostly through a publicly funded national health insurance model; on the other hand, in the U.S., there is great dependence on private financing and delivery of care.¹³ One of the key challenges of the U.S. healthcare system is that the lack of a publicly funded model has led to accessibility challenges, with cost being one of the main barriers to care.¹³ Therefore, caution must be exercised when using data from the U.S. on prostate cancer screening for Black men in the Canadian context.

Nyame et al provide various targeted PCa screening models for men in the U.S.¹⁴ One of their models predicted that an annual PCa screening program for Black men aged 45–69 would achieve a mortality reduction of 26–29%, with an associated 51–61 overdiagnoses per 1000 men. Overdiagnosis entails PCas that would not have reduced life expectancy if not diagnosed or treated. Despite the overdiagnosis, the authors emphasized that the mortality reduction would be beneficial compared to historical cohorts and limiting screening to men under 70 would help prevent overdiagnosis.

The potential benefits linked to PSA screening for at-risk marginalized populations can be further enhanced by reducing or eliminating other relevant PSA screening barriers, thus increasing participation. Jandorf et al observed that free, community-based PCa screening programs were an effective approach to engage Black and Hispanic men, who may have otherwise

not undergone testing.¹⁵ At the end of the program, nearly 90% of the participants opted to have a screening PSA.¹⁵ Another study by Weinrich et al suggested that addressing knowledge gaps through education can also boost screening rates.¹⁶ They found that 61% of 1211 African-American men who took part in an educational program went on to enroll in a free PCa screening program.

Reducing the financial burden and raising awareness regarding PCa screening is vital, but there are additional challenges to address, especially for marginalized populations. In addition to financial barriers, Lee et al found that African-Americans reported higher screening fears and PCa worries than their Caucasian counterparts.¹⁷ Fear of diagnosis, which stems from the lack of knowledge, and distrust of medical professionals, were also common reasons among Black men for choosing to opt out of PSA screening.¹⁸

One can only speculate that similar factors may impact Indigenous men, and mistrust of medical establishments can pose a barrier for Indigenous men as well.¹⁹ It is clear that mistrust exists for both of these marginalized populations of men, thus, innovative approaches involving stakeholders and healthcare providers from these communities are potential ways to mitigate barriers. Moreover, it is possible that these marginalized populations may have different ideals and value in regard to the ultimate value on screening.²⁰ Additionally, any approach to optimize screening of Black and Indigenous men in Canada will require further investigation of the social determinants of health in these two populations with respect to PCa.

No-cost PSA screening of at-risk marginalized men would constitute only one small part of a robust PCa screening program. Integrated screening programs should aim to provide Black and Indigenous men with education on PCa in a way that aims to empower them, so that they understand the benefits of making an earlier diagnosis of PCa. Additionally, these men need to understand that localized PCa can be treated effectively.

A PCa screening program that will engage Black and Indigenous men will need to overcome years of mistrust that these populations have in the healthcare system. In an effort to build trust with these groups, screening programs should actively collaborate with the target population and engage key stakeholders in the development of the program. For example, in British Columbia, a key stakeholder could be the First Nations Health Authority (FNHA).¹⁹ The FNHA has taken responsibility for health services for First Nations that were previously provided by Health Canada.¹⁹

The public health impacts of FNHA have been positive, such as improving service time and extending telehealth coverage.¹⁹

Unique approaches, such as offering screening at important community establishments, may provide opportunities to offer valuable PCa screening. For example, in New York City, it was found that community-based diabetes testing was effective in identifying and engaging Black men with unidentified diabetes.²¹ Men from these marginalized populations will need to be involved as leaders of effective screening programs. They will need to advocate for its implementation and provide direct guidance on the benefits/risks of screening to men from their respective population groups.

Mobile screening operations can take up a variety of physical forms, from trailers to unused shopping spaces in malls. An essential part of mobile screening is to raise awareness in marginalized communities.²² Moreover, this becomes exceedingly important when patients may not fully understand the breadth of services available.²² Mobile screening programs have the potential to raise awareness of PCa and support screening efforts.²² Ideally, healthcare professionals from these marginalized populations would be involved in providing the PSA screening to their respective communities.

These are some examples that could be further developed within the contexts of specific communities. It is necessary to understand the importance of discussing with these communities before implementing any intervention, as this may otherwise perpetuate the cycle of marginalization. Figure 1 highlights key components of a screening program.

Additionally, as suggested by Cooperberg,²³ there is considerable evidence that highlights the need to improve screening for members of marginalized populations. For the reasons outlined, we strongly advocate for the implementation of a free and universally available PSA screening program for Black and Indigenous men living in Canada. Furthermore, we recommend instituting a program to reduce the barriers to PCa screening for at-risk marginalized men and engaging with stakeholders from marginalized communities. While our focus is on these groups, it must be recognized that screening improves PCa-specific survival for all men, and universal access should be considered for all in a publicly funded health system.

COMPETING INTERESTS: Dr. St-Laurent has received speaker honoraria from Bayer and EMB Serono. Dr. Black has been an advisory board member for AbbVie, Astellas, AstraZeneca, Bayer, BMS, EMD Serono, Ferring, Janssen, MDxHealth, Merck, Minogue, Nonagen, Nanology, Pfizer, Protara, QED, Roche, Sanofi, Sesen, STIMIT, Therelase, UroGen, and Verity and a speakers' bureau member for Bayer, BioSytent, Pfizer, Sanofi, and TerSera;




Figure 1. Key components of a prostate cancer screening program for Black and Indigenous men. PSA: prostate-specific antigen

holds a patent for Veracyte; and has participated in a clinical trial supported by Veracyte. All remaining authors do not report any competing personal or financial interests related to this work.

This paper has been peer reviewed.

REFERENCES

1. Cancer.ca. Prostate Cancer Statistics, [updated November 2023; cited August 6, 2023]. Available at: <https://cancer.ca/en/cancer-information/cancer-types/prostate/statistics>. Accessed August 1, 2023.
2. Fränlund M, Månsson M, Godtman RA, et al. Results from 22 years of followup in the Göteborg randomized population-based prostate cancer screening trial. *J Urol* 2022;208:292-300. <https://doi.org/10.1097/JU.0000000000002696>
3. Hugosson J, Roobol MJ, Månsson M, et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. *Eur Urol* 2019;76:43-51. <https://doi.org/10.1016/j.eururo.2019.02.009>
4. Mason RJ, Marzouk K, Finelli A, et al. Update - 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging - summary of changes. *Can Urol Assoc J* 2022;16:86-7. <https://doi.org/10.5489/cuoj.7832>
5. Mottet N, Cornford P, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Edn presented at the EAU Annual Congress Milan. 2023.
6. Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part I: Prostate cancer screening. *J Urol* 2023;210:46-53. <https://doi.org/10.1097/JU.0000000000003491>
7. Rawla P. Epidemiology of prostate cancer. *World J Oncol* 2019;10:63-89. <https://doi.org/10.14740/wjon1191>
8. Gov.bc.ca Ministry of Health: Prostate cancer part 1: Diagnosis and referral in primary care. [Updated April 15, 2020; cited August 5, 2023]. Available at: <https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/prostate-cancer-part-1>. Accessed August 1, 2023.

9. Lillard JW Jr, Moses KA, Mahal BA, et al. Racial disparities in Black men with prostate cancer: A literature review. *Cancer* 2022;128:3787-95. <https://doi.org/10.1002/cncr.34433>
10. Kiciak A, Clark W, Uhlich M, et al. Disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non-Indigenous men in a universal healthcare system. *Cancer* 2023;129:2864-70. <https://doi.org/10.1002/cncr.34812>
11. James LJ, Wong G, Craig JC, et al. Men's perspectives of prostate cancer screening: A systematic review of qualitative studies. *PLoS One* 2017;12:e0188258. <https://doi.org/10.1371/journal.pone.0188258>
12. Otiano K, Nkonge B, Olaiya OR, et al. Prostate cancer screening in Black men in Canada: A case for risk-stratified care. *CMAJ* 2022;194:E1411-5. <https://doi.org/10.1503/cmaj.220452>
13. Ridic G, Gleason S, Ridic O. Comparisons of health care systems in the United States, Germany and Canada. *J Acad Med Sci of Bosnia Herzegovina* 2012;24:112-20. <https://doi.org/10.5455/msm.2012.24.112-120>
14. Nyame YA, Gulati R, Heijnsdijk EAM, et al. The impact of intensifying prostate cancer screening in Black men: A model-based analysis. *J Natl Cancer Inst* 2021;113:1336-42. <https://doi.org/10.1093/inci/djab072>
15. Jandorf L, Chang M, Smith K, et al. Community-based free prostate cancer screening program. *Progress in Community Health Partnerships: Research, Education, and Action*. 2007;1:215-20. <https://doi.org/10.1353/cpr.2007.0024>
16. Weinrich S, Boyd M, Weinrich M, et al. Increasing prostate cancer screening in African American men with peer-educator and client-navigator interventions. *J Cancer Educ* 1998;13:213-19.
17. Lee D, Considine N, Spencer B. Barriers and facilitators to digital rectal examination screening among African-American and Afro-Caribbean men. *J Urol* 2011;77:891-8. <https://doi.org/10.1016/j.urol.2010.11.056>
18. Reynold D. Prostate cancer screening in African American men: Barriers and methods for improvement. *American J Men's Health*. 2008;2:172-7. <https://doi.org/10.1177/1557988307312784>
19. Vogel L. Broken trust drives native health disparities. *CMAJ* 2015;187: E9-E10. <https://doi.org/10.1503/cmaj.109-4950>
20. Vapiwala N, Miller D, Laventure, B. Stigma, beliefs, and perceptions regarding prostate cancer among Black and Latino men and women. *BMC Public Health* 2021;1:758. <https://doi.org/10.1186/s12889-021-10793-x>
21. Osorio M, Ravenell JE, Sevick MA. Community-based hemoglobin A_{1c} testing in barbershops to identify black men with undiagnosed diabetes. *JAMA Intern Med* 2020;180:596-97. <https://doi.org/10.1001/jamainternmed.2019.6867>
22. Maghul M, Cazzaniga W, Croft F, et al. Mobile health solutions for prostate cancer diagnostics - A systematic review. *Clinics and Practice* 2023;13:863-72. <https://doi.org/10.3390/clinpract13040078>
23. Cooperberg, M. R. Can early prostate cancer screening help address mortality disparities among Black men? *J Natl Cancer Inst* 2023;1-3. <https://doi.org/10.1093/inci/djad217>

CORRESPONDENCE: Dr. Nilanga Aki Bandara, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; n.bandara@alumni.ubc.ca